Rapid and simple screening of CRISPR guide RNAs (gRNAs) in cultured cells using adeno-associated viral (AAV) vectors

• Verfasst von: Fakhiri, Julia [VerfasserIn]
• Verfasst von: Nickl, Manuela [VerfasserIn]
• Verfasst von: Grimm, Dirk [VerfasserIn]
• Titel: Rapid and simple screening of CRISPR guide RNAs (gRNAs) in cultured cells using adeno-associated viral (AAV) vectors
• Verf.angabe: Julia Fakhiri, Manuela Nickl, Dirk Grimm
• E-Jahr: 2019
• Jahr: 26 March 2019
• Umfang: 16 S.
• Fussnoten: Gesehen am 03.06.2020
• Titel Quelle: Enthalten in: CRISPR gene editing
• Ort Quelle: New York, NY : Humana Press, 2019
• Jahr Quelle: 2019
• Band/Heft Quelle: (2019), Seite 111-126
• ISBN Quelle: 978-1-4939-9170-9
• DOI: doi:10.1007/978-1-4939-9170-9_8
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: AAV
• Sach-SW: Adeno-associated virus
• Sach-SW: CRISPR
• Sach-SW: gRNA
• Sach-SW: GuideRNA
• Sach-SW: T7E1 assay
• K10plus-PPN: 1699304408

Abstract

Genome editing reagents including the recently introduced CRISPR/Cas9 system have become established and widely used molecular tools to answer fundamental biological questions and to target and treat genetic diseases. The CRISPR system, originally derived from bacteria and archaea, can be delivered into cells using different techniques, comprising (1) transfection of mRNA or plasmid DNA, (2) electroporation of plasmid DNA or the Cas9 protein in a complex with a g(uide)RNA, or (3) use of nonviral or viral vectors. Among the latter, Adeno-associated viruses (AAVs) are particularly attractive owing to many favorable traits: (1) their apathogenicity and episomal persistence, (2) the ease of virus production and purification, (3) the safe handling under lowest biosafety level 1 conditions, and (4) the availability of numerous natural serotypes and synthetic capsid variants with distinct cell specificities. Here, we describe a fast and simple protocol for small-scale packaging of CRISPR/Cas9 components into AAV vectors. To showcase its potential, we employ this method for screening of gRNAs targeting the murine miR-122 locus in Hepa1-6 cells (using AAV serotype 6, AAV6) or the 5′LTR of the human immunodeficiency virus (HIV) in HeLaP4-NLtr cells (using a synthetic AAV9 variant). We furthermore provide a detailed protocol for large-scale production of purified AAV/CRISPR vector stocks that permit higher cleavage efficiencies in vitro and are suitable for direct in vivo applications.